ES2348536T3 - Uso de endoperoxidos para el tratamiento de infecciones causadas por flaviviridae, incluyendo el virus de la hepatitis c, de la diarrera viral bovina y de la fiebre porcina clasica. - Google Patents

Uso de endoperoxidos para el tratamiento de infecciones causadas por flaviviridae, incluyendo el virus de la hepatitis c, de la diarrera viral bovina y de la fiebre porcina clasica. Download PDF

Info

Publication number
ES2348536T3
ES2348536T3 ES03781492T ES03781492T ES2348536T3 ES 2348536 T3 ES2348536 T3 ES 2348536T3 ES 03781492 T ES03781492 T ES 03781492T ES 03781492 T ES03781492 T ES 03781492T ES 2348536 T3 ES2348536 T3 ES 2348536T3
Authority
ES
Spain
Prior art keywords
artemisinin
hepatitis
group
treatment
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES03781492T
Other languages
English (en)
Spanish (es)
Inventor
Jan Vandenkerckhove
Eric Peys
Benedikt Sas
Johan NEYTS
Johan Van Hemel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kemin Foods LC
Original Assignee
Kemin Foods LC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kemin Foods LC filed Critical Kemin Foods LC
Application granted granted Critical
Publication of ES2348536T3 publication Critical patent/ES2348536T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/282—Artemisia, e.g. wormwood or sagebrush
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES03781492T 2002-10-31 2003-10-29 Uso de endoperoxidos para el tratamiento de infecciones causadas por flaviviridae, incluyendo el virus de la hepatitis c, de la diarrera viral bovina y de la fiebre porcina clasica. Expired - Lifetime ES2348536T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42268302P 2002-10-31 2002-10-31
US422683P 2002-10-31

Publications (1)

Publication Number Publication Date
ES2348536T3 true ES2348536T3 (es) 2010-12-09

Family

ID=32312544

Family Applications (1)

Application Number Title Priority Date Filing Date
ES03781492T Expired - Lifetime ES2348536T3 (es) 2002-10-31 2003-10-29 Uso de endoperoxidos para el tratamiento de infecciones causadas por flaviviridae, incluyendo el virus de la hepatitis c, de la diarrera viral bovina y de la fiebre porcina clasica.

Country Status (11)

Country Link
US (1) US7842719B2 (https=)
EP (1) EP1585524B1 (https=)
JP (1) JP4594734B2 (https=)
CN (1) CN100430061C (https=)
AT (1) ATE473745T1 (https=)
AU (1) AU2003287259A1 (https=)
CA (1) CA2501584C (https=)
DE (1) DE60333392D1 (https=)
ES (1) ES2348536T3 (https=)
PT (1) PT1585524E (https=)
WO (1) WO2004041176A2 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004029651D1 (de) 2003-02-12 2010-12-02 Univ Georgetown Verwendung von artemisinin zur behandlung von durch onkogene viren gebildeten tumoren und zur behandlung von viralen infektionen
ES2245248B1 (es) * 2004-06-09 2007-02-16 Universidad De Salamanca Uso de la artemisinina y sus derivados en la fabricacion de medicamentos utiles como agentes antiviricos.
KR100824106B1 (ko) * 2006-05-30 2008-04-21 주식회사 씨티씨바이오 흰반점바이러스를 치료 또는 예방하기 위한 조성물 및 방법
WO2008010620A1 (en) * 2006-07-21 2008-01-24 Ben's Lab Co., Ltd. Composition comprising the crude drug extracts for improving liver function
AU2007286754A1 (en) * 2006-08-25 2008-02-28 Viropharma Incorporated Identification and characterization of HCV replicon variants with reduced susceptibility to HCV-796, and methods related thereto
WO2009155379A2 (en) * 2008-06-17 2009-12-23 Hhv-6 Foundation Artemisinin and derivatives thereof as antivirals
CN102731464B (zh) * 2011-04-12 2014-07-23 沈阳药科大学 一个倍半萜内酯化合物、制备方法及其应用
WO2013006795A2 (en) 2011-07-07 2013-01-10 Humanitas International Foundation Antiviral compositions and methods of their use
US20130012470A1 (en) * 2011-07-07 2013-01-10 Humanitas Technology, LLC Antiviral compositions and methods of their use
PL2838903T3 (pl) 2012-04-18 2018-04-30 The Hong Kong University Of Science And Technology Sposoby i kompozycje do leczenia zakażeń wirusowych
FR2989588A1 (fr) * 2012-04-19 2013-10-25 Centre Nat Rech Scient Composes pour la prevention ou le traitement des infections par des virus de la famille des flaviviridae
CN102755316A (zh) * 2012-07-16 2012-10-31 中国科学院武汉病毒研究所 青蒿素及其衍生物在制备治疗丙型肝炎病毒药物中的应用
MX2019004029A (es) 2016-10-07 2019-09-27 Navidea Biopharmaceuticals Inc Compuestos y metodos para diagnosis y tratamiento de infecciones virales.
GB201805665D0 (en) * 2018-04-05 2018-05-23 Univ Nottingham Antiviral Compounds And Methods
US20210196676A1 (en) * 2018-05-30 2021-07-01 The Board Of Regents Of The University Of Texas System Treatment of viral infections and virally associated lesions with sequiterpene lactones
GB2613460B (en) * 2020-04-20 2025-07-23 Lloyd Hung Loi Tran Pharmaceutical Compositions for use in methods for the prophylaxis or treatment of COVID such as COVID-19; and compound for use in the treatment of a
CN112245424B (zh) * 2020-10-19 2021-09-21 中国医学科学院医药生物技术研究所 一种没药烷倍半萜结构类似物在制备抗冠状病毒药物中的用途
CN112294795B (zh) * 2020-11-17 2022-03-29 北京化工大学 蒿甲醚在治疗和预防柯萨奇病毒感染中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW198722B (https=) 1990-05-07 1993-01-21 Hoechst Ag
CN1058717A (zh) * 1990-08-08 1992-02-19 中国人民解放军军事医学科学院微生物流行病研究所 抗疟新药—复方蒿甲醚及其制备方法
CN1035767C (zh) * 1992-11-10 1997-09-03 罗宣德 新的青蒿素衍生物及其用途
CN1105238A (zh) * 1992-11-10 1995-07-19 中国预防医学科学院病毒学研究所 抗aids病毒的药物组合物
WO1995003311A1 (en) * 1993-07-19 1995-02-02 Xuande Luo Qinghaosu derivatives against aids
DE4415539C2 (de) * 1994-05-03 1996-08-01 Osama Dr Dr Med Omer Pflanzen mit virustatischer und antiviraler Wirkung
CN1049435C (zh) * 1994-11-09 2000-02-16 中国科学院上海药物研究所 含苯基和杂环基的青蒿素衍生物及其制备方法
DE19902924A1 (de) 1999-01-26 2000-08-03 Hassan Jomaa Verwendung von phosphororganischen Verbindungen zur prophylaktischen und therapeutischen Behandlung von Infektionen
CN1135974C (zh) 2000-08-23 2004-01-28 重庆健桥医药开发有限公司 抗疟药新药复方双氢青蒿素
AU2001295979A1 (en) 2000-10-20 2002-04-29 Ajinomoto Co., Inc. Medicinal compositions, dose and method for treating malaria
DE602004029651D1 (de) * 2003-02-12 2010-12-02 Univ Georgetown Verwendung von artemisinin zur behandlung von durch onkogene viren gebildeten tumoren und zur behandlung von viralen infektionen

Also Published As

Publication number Publication date
EP1585524A2 (en) 2005-10-19
EP1585524A4 (en) 2007-10-10
CA2501584C (en) 2009-03-10
CA2501584A1 (en) 2004-05-21
AU2003287259A1 (en) 2004-06-07
WO2004041176A2 (en) 2004-05-21
DE60333392D1 (de) 2010-08-26
CN100430061C (zh) 2008-11-05
US7842719B2 (en) 2010-11-30
PT1585524E (pt) 2010-10-19
US20050059647A1 (en) 2005-03-17
WO2004041176A3 (en) 2004-10-07
EP1585524B1 (en) 2010-07-14
AU2003287259A8 (en) 2004-06-07
JP4594734B2 (ja) 2010-12-08
CN1711091A (zh) 2005-12-21
JP2006504787A (ja) 2006-02-09
ATE473745T1 (de) 2010-07-15

Similar Documents

Publication Publication Date Title
ES2348536T3 (es) Uso de endoperoxidos para el tratamiento de infecciones causadas por flaviviridae, incluyendo el virus de la hepatitis c, de la diarrera viral bovina y de la fiebre porcina clasica.
Momattin et al. A Systematic Review of therapeutic agents for the treatment of the Middle East Respiratory Syndrome Coronavirus (MERS-CoV)
US20110206636A1 (en) Use of Endoperoxides for the Treatment of Infections Caused by Flaviviridae, Including Hepatitis C, Bovine Viral Diarrhea and Classical Swine Fever Virus
KR20120088743A (ko) 특정 ｈｃｖ ｎｓ５ａ 억제제 및 ｈｃｖ ｎｓ３ 프로테아제 억제제의 조합물
CN106902347A (zh) 亲环孢素抑制剂的用途
EP3785718B1 (en) Pharmaceutical composition for prevention or treatment of flavivirus infectious disease
US11999806B2 (en) Broad-spectrum polypeptide against enterovirus and application thereof
Kern et al. Herpesvirus hominis infection in newborn mice: treatment with interferon inducer polyinosinic-polycytidylic acid
JP2009519265A (ja) ウイルス感染を処置するためのジアリールウレア
ES2982915T3 (es) Interferones híbridos para tratar infecciones virales
WO2022079205A1 (en) Use of ifn-alpha polypeptides for the treatment of coronavirus infections
CN119950474A (zh) 异绿原酸c在制备抗呼吸道合胞病毒a型株药物中的应用
CN109045011B (zh) 酪氨酸激酶抑制剂在制备抗基孔肯雅病毒药物中的应用
EP2683369B1 (en) Multiantivirus compound, composition and method for treatment of virus diseases
CN110664988A (zh) H-Lys-Trp-Lys-OH在制备抗牛肠道病毒药物中的应用
CN1535724B (zh) 重组人干扰素在制备预防严重性急性呼吸道综合征的药物的用途
Griffin Therapy of viral infections of the central nervous system
CN114903897A (zh) 千金藤素在制备抗蜱传脑炎病毒药物中的应用
ES3062539T3 (en) Drug combinations of entecavir and a tlr7 agonist for use in the treatment of hbv
CN110179785B (zh) 魏特酮在制备治疗或预防手足口病药物中的应用
WO2006033453A1 (ja) インターフェロン作用物質の活性増強剤
World Health Organization Progress in the development and use of antiviral drugs and interferon: report of a WHO Scientific Group [meeting held in Geneva from 10 to 13 March 1987]
BG65190B1 (bg) Средство за химиотерапия и химиопрофилактика на флавивирусни инфекции
UA20904U (en) Method for stimulating production of endogenous interferon